Cancer Chemotherapy and Kidney

Objective & Hypothesis:The nephrotoxicity of cancer chemotherapy varies from mild serum creatinine level elevation to end stage kidney failure depending on the type and dosage of the drug.

📊

Key Findings & Data:The mortality and morbidity rates can be decreased by preventing the chemotherapy-induced nephrotoxicity.

💡

Conclusion & Impact:Key words: Cancer, Chemotherapy, Nephrotoxicity, Mortality

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Kanser · Kemoterapi · Nefrotoksisite

Abstract

The nephrotoxicity of cancer chemotherapy varies from mild serum creatinine level elevation to end stage kidney failure depending on the type and dosage of the drug. Saline-based hydration confer protection against chemotherapy-induced nephrotoxicity. The mortality and morbidity rates can be decreased by preventing the chemotherapy-induced nephrotoxicity. In this compilation, we aimed evaluating the mechanisms of chemotherapy induced nephrotoxicity of the most frequently observed cancer drugs and kidney disorder depending on chemotherapy. Key words: Cancer, Chemotherapy, Nephrotoxicity, Mortality

Özet

Kanser ilaçlarının tipine ve dozuna bağlı olarak serum kreatininin hafif yükselmesinden son dönem böbrek yetmezliğine kadar ciddi boyutta böbrek bozukluğu görülebilmektedir. Kemoterapi öncesi sağlanacak yeterli hidrasyonla nefrotoksisite büyük ölçüde önlenebilir. Kemoterapiye bağlı nefrotoksisitenin önlenmesi ile hastaların mortalite ve morbidite oranı azaltılabilir. Bu derlemede kemoterapiye bağlı böbrek bozukluğunu ve nefrotoksisitesi en sık gözlenen kanser ilaçlarının nefrotoksik etki mekanizmalarını değerlendirmeyi amaçladık. Anahtar kelimeler: Kanser, Kemoterapi, Nefrotoksisite, Mortalite

Keywords

Kanser Kemoterapi Nefrotoksisite Mortalite Cancer Chemotherapy Nephrotoxicity Mortality

🔖

Cite This Article

ERKURT, M. A., KUKU, İ., KAYA, E., AYDOĞDU, İ. (2009). Cancer Chemotherapy and Kidney. Turgut Özal Tıp Merkezi Dergisi, Cilt: 16 Sayı: 1, 63–68. https://ajindex.com/articles/1010034

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (13)

Kintzel PE. Anticancer drug-induced kidney disorders. Incidence, prevention and management. Drug Safety 2001; 24:19-38.
Boogaard PJ, Nagelkerke JF, Mulder GJ: Renal proximal tubular cells in suspension or in primary culture as in vitro models to study nephrotoxicity. Chem. Biol. Interact 1990; 76: 281-291.
Fillastre JP, Godin M. Drug-induced nephropathies. In Davison AM, Cameron JS, Grünfeld JP, et al. Oxford Textbook of Clinical Nephrology. New York: Oxford University Press 1998; 2645-2657.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
Meister LA, Meadows AT. Late effects of childhood cancer therapy. Curr Probl Prediatr 1993; 23,102-131.
Ikarashı Y, Kakıhara Y, Imaı C et al. Glomerular dysfunction, independent of tubular dysfunction, induced by antineoplastic chemotherapy in children. Pediatrics International 2004; 46: 570- 575. Fels LM, Bokemeyer C, van Rhee J. Evaluation of late nephrotoxicity in long-term survivors of Hodgkin’s disease. Oncology,1996; 53:73-78.
Skinner R, Pearson AD, English MW. Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer 1998; 77: 1677-1682.
Seiler MW, Rennke HG, Venatachalam MA, Cotran RS. Pathogenesis of polycation-induced alteration’s ‘fusion’ of glomerular epithelium. Lab. Invest 1977; 36:48-61. Andrews P. Morphological alterations of the glomerular (visceral) epithelium in response to pathological and experimental situations. J Electron Microsc Tech 1988; 9: 115- 124. Watanabe A, Kakihara T, Hara M et al. Morphological differences between glomerular epithelial cells (GEC) excreted during chemotherapy with antineoplastic drugs and GEC excreted in renal diseases. Pediatr. Int 2001; 43: 587-591.
Fajardo LF, Eltringham JR, Stewart JR, Klauber MR. Adriamycin nephrotoxicity. Lab. Invest 1980; 43: 242-253.
Harmon WE, Cohen HJ, Schneeberger EE, Grupe WE. Chronic renal failure in children treated with methyl CCNU. NEJM 1979; 300: 1200-1203. Alpers C Cotran RS. Neoplasia and Glomerular injury. Kidney International 1986; 30: 465-473.
Dabbs DJ, Striker LMM, Mignon F, Striker G. Glomeruler lesions in lymphomas and leukemias. Am J Med 1986; 80:63-70.
Glassock RJ, Massry SG. Neoplasia Textbook of Nephrology. Glassock RJ, Massry SG(eds). Williams and Wilkins, Baltimore 1996: 1117-1123.
Loehrer PJ, Einhorn LH: Drugs five years later Cisplatin. Ann Intern Med 1984; 100: 704-713. Emmerson BT. Toxic Nephrophaty. Oxford Textbook of Medicine 3rd Ed. Vol.